Literature DB >> 12611202

[Benign prostatic hyperplasia: patients' perception of medical treatment and their expectations. Results of a french survey involving patients treated with finasteride].

P Teillac1.   

Abstract

Benign prostatic hyperplasia (BPH) is increasingly common in medical practice, as a result of the inevitable aging of the population. The current therapeutic strategy includes three alternatives: watchful waiting, medical treatment and invasive therapy. Finasteride is one of the pharmacological options available. Many clinical studies have demonstrated its efficacy and good safety profile in patients with BPH. The survey we report provides new insights into what has to date been a purely therapeutic approach by taking into consideration patients' expectations and their perception of finasteride treatment. Results indicate that the main preoccupation for patients with BPH is that the pharmacological treatment will reduce the risk of major urological complications and the need for surgery (treatment characteristics considered as very or extremely important by 88 and 93% of patients, respectively). Decreasing symptoms and improving quality of life take second place after these primary concerns. Patient perception of finasteride is excellent. Nearly all patients are satisfied by the efficacy of the treatment, 89% of them reporting good to extremely good improvement of symptoms, the rapid onset of relief being particularly important. The efficacy of finasteride is not hindered by any tolerability issues and is further strengthened by its ease of use. Although this novel survey includes a number of biases, it nevertheless demonstrates that treatment of BPH with finasteride is well accepted by patients and satisfies their expectations. In addition, it provides a mass of general epidemiological data on patients with BPH, as well as on current medical practice regarding this condition.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12611202

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  4 in total

1.  Patient's and physician's behavior on the management of benign prostatic hyperplasia among the patients at the risk of clinical progression. A multicenter noninterventional trial in Slovakia by "Prostate and Expectations of Treatment: Epidemiology Research" (PETER) study group.

Authors:  Peter Weibl; Peter Laurinc; Roman Tomaškin; Tobias Klatte; Shahrokh Shariat F; Miroslav Helbich; Danica Fačkovcova; Peter Bujdák
Journal:  Wien Klin Wochenschr       Date:  2015-03-28       Impact factor: 1.704

2.  Patient's behavior and attitudes toward the management of benign prostatic hyperplasia among patients with the risk of disease progression: prospective study by "Prostate and Expectations of Treatment Epidemiology Research (PETER) study group".

Authors:  Peter Weibl; Tobias Klatte; Peter Laurinc; Roman Tomaškin; Shahrokh F Shariat; Miroslav Helbich; Danica Fackovcova; Peter Bujdák
Journal:  Wien Klin Wochenschr       Date:  2014-12-02       Impact factor: 1.704

3.  Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey.

Authors:  M Emberton; M Marberger; J de la Rosette
Journal:  Int J Clin Pract       Date:  2007-11-19       Impact factor: 2.503

Review 4.  Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management.

Authors:  M Emberton; E B Cornel; P F Bassi; R O Fourcade; J M F Gómez; R Castro
Journal:  Int J Clin Pract       Date:  2008-05-08       Impact factor: 2.503

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.